Lezhu Group Divulge: 200 Million New Products Will Be Listed Ahead Of Schedule With Equity Shareholders.

< p > according to internal knowledge, the company and equity shareholder Kang Kang Yuan Pharmaceutical Group, < a href= "http://www.91se91.com/" > shares < /a > Co., Ltd. increased their total assets by 200 million yuan according to their respective shareholding ratio of Li Zhu mAb Biotechnology Co., Ltd., the total amount of investment increased to RMB $102 million, and the company invested 102 million yuan, and Jian Kang Yuan invested 98 million yuan. After the capital increase, the registered capital of Li Zhu mAb increased to 500 million yuan, and the shareholding ratio of Li Zhu mAb of the company and Kang Kang Yuan remained unchanged at 51% and 49% respectively.

< /p >

< p style= "text-align: center" > < img border= "0" align= "center" alt= "" src= "" /uploadimages/201406/06/20140606111351_sj.JPG "/" < > > "

< p > the original superior varieties of Shenzhu group, Shenqi Fuzheng Injection and sex hormones, have been increasing rapidly under the impetus of "a href=" http://www.91se91.com/ "marketing < /a > reform, and the new varieties of mouse nerve growth factor, bright proprin microsphere, and elaprazole have increased explode. The company's prescription medicine business is in a fast growing stage, and the product echelons of the company in the field of prescription drugs are favored by the market participants in the long run.

The company said that the company has established the a href= "http://www.91se91.com/" and "/a" technology, which is necessary for the development of the technology, and has established a core R & D team and a management team with rich experience, and invested in the newly built pilot and laboratory in the Li Zhu Industrial Park.

At present, 7 products have been developed, of which the recombinant human anti tumor necrosis factor alpha monoclonal antibody for injection has been approved by the State Food and Drug Administration for phase I clinical trials.

The main purpose of this increase is to meet the needs of the company's future business capital, ensure its smooth implementation in research projects, and promote the company's strategic goals in the field of biopharmaceutical industry.

< /p >